NATURAL HEALTH TRENDS CORP (NHTC)
NASDAQConsumer DiscretionarySpecialty RetailSnapshot 2026-09-09
$1.59-2.45%
Close 2026-09-09 · 1-day change
NASDAQConsumer DiscretionarySpecialty RetailSnapshot 2026-09-09
Broken: Primary pillar broken — Improve operating income from negative levels: Operating income not reported; Q2 FY26 EPS -0.05.
The company bought back 25.5% of its shares in 2026-Q1. It keeps paying dividends, though smaller recently. Operating losses are shrinking but still negative. These show efforts to improve value and profits.
The company is losing money and sales are shrinking. Revenue is expected to fall 13% next year. The stock price dropped 41% from its high. These show the business is struggling.
The price is about 47% below our fair value near $3. Analysts expect revenue to drop 13%. This matches the weak outlook and losses.
Breaks if: Dividend per share falls below $0.1 next 4 quarters
Continue paying quarterly cash dividends, with a reduction to $0.10 per share starting in 2026-Q1.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity with a medium confidence level. The current thesis state indicates that NHTC is under pressure due to recent earnings misses and a fragile earnings quality.
The market seems to price in a justified valuation that is cheap compared to peers, reflecting the company's weak execution. There is an expectations gap, suggesting that investors anticipate further challenges ahead.
Fundamentals are likely to remain weak in the near term, as indicated by a high probability of an earnings miss. Management's focus on cost restructuring shows some promise, but overall performance has not improved significantly.
The thesis hinges on several factors, including management's ability to avoid further earnings guidance cuts and the impact of inflation on consumer discretionary spending. Additionally, positive performance from sector leaders could provide a lift.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company resumed its share repurchase program, which supports its capital allocation strategy. This move indicates confidence in its financial position despite ongoing challenges. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Management declared and paid a quarterly dividend of $0.10 per share in 2026-Q1, down from $0.20 per share in 2025-Q4 as anticipated. Dividend payments continue but at a reduced rate, consistent with management's stated plan.
“Declared a quarterly cash dividend of $0.10 per share.”
“Anticipate a reduction in our quarterly cash dividend to $0.10 per share beginning in the first quarter next year.”
Breaks if: Operating income remains negative through FY26
Breaks if: Repurchased shares fall short of 2,900,000 by 2026-Q1
Continue the share repurchase program with $15.9 million available for buybacks, subject to market conditions.
Stated as a priority in 2 of last 2 quarters. The Board authorized resuming stock repurchases with about $16 million available as of 2026-Q2. Total cash and marketable securities declined from $21.2 million in 2026-Q1 to $18.6 million in 2026-Q2, reflecting repurchases and dividends. The trajectory shows active capital allocation via buybacks consistent with management's stated priority.
“Board of Directors authorized resuming stock repurchases, with approximately $16 million available.”
“Total cash, cash equivalents and marketable securities were $21.2 million at March 31, 2026, down from $28.9 million due to repurchase of shares.”
Over the next 1 to 3 years, NHTC's outlook remains uncertain, with significant risks and challenges ahead. Not investment advice.